Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine
Disease Category: Multiple Sclerosis
Location: United States, IL
A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).
The purpose of this study is to evaluate patient-reported outcomes and physician assessment of a change in therapy for patients with remitting-relapsing multiple sclerosis when changing a patient's current multiple sclerosis therapy to fingolimod or maintaining the current therapy.
Please contact Alexian Brothers for more information on participation.
CW ID: 176860
Date Last Changed:
July 22, 2013
Alexian Brothers Hospital Network800 Biesterfield Road
Brock Building First FloorElk Grove Village, IL 60007Phone: 847-593-8553
Alexian Brothers Hospital Network
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.